1;Dedications;5 2;Foreword;7 3;Introduction;8 4;Table of Contents;10 5;1 CONCURED: Defining the Leading Edge in Research of Adverse Eff ects of Treatment for Adult-Onset Cancers;12 5.1;1.1 Introduction;12 5.2;1.2 Research Infrastructure for Studies of Cancer Survivorship;12 5.3;1.3 A Platform for Studies of Gene-Environment Interactions;14 5.4;1.4 Development of Epidemiologic Methods and Predictive Models;14 5.5;1.5 Evidence-Based Clinical Practice Guidelines;14 5.6;1.6 A Trans-disciplinary Approach;15 5.6.1;Comment;15 5.6.2;Acknowledgement;16 5.7;References;16 6;2 Bioimaging In Vivo to Discern the Evolution of Late Eff ects Temporally and Spatially;18 6.1;2.1 Introduction;18 6.2;2.2 Lung Injury;19 6.3;2.3 Heart Injury;21 6.3.1;2.3.1 SPECT;22 6.3.2;2.3.2 MRI;22 6.3.3;2.3.3 Cardiac PET;22 6.4;2.4 Liver Injury;24 6.4.1;2.4.1 CT Perfusion Studies;24 6.4.2;2.4.2 MRI;24 6.5;2.5 Brain Injury;25 6.5.1;2.5.1 SPECT;25 6.5.2;2.5.2 PET;25 6.5.3;2.5.3 MRI;27 6.5.4;2.5.4 Magnetic Resonance Spectroscopy;27 6.5.5;2.5.5 Functional Magnetic Resonance Imaging;28 6.6;2.6 Parotid Gland Injury;28 6.6.1;2.6.1 SPECT and PET;28 6.6.2;2.6.2 MRI;28 6.7;2.7 Conclusions;28 6.7.1;Acknowledgements;28 6.8;References;30 7;3 Association Between Single Nucleotide Polymorphisms and Susceptibility for the Development of Adverse Eff ects Resulting from Radiation Therapy;35 7.1;3.1 Summary;35 7.2;3.2 Introduction;35 7.3;3.3 Predictive Assays;36 7.4;3.4 Candidate Gene Studies;37 7.5;3.5 Genome Wide SNP Association Studies;37 7.6;3.6 Conclusion;40 7.6.1;Acknowledgements;40 7.7;References;40 8;4 Prospective Second-Cancer Risk Estimation for Contemporary Radiotherapeutic Protocols;43 8.1;4.1 Introduction: Radiotherapy-Related Second-Cancer Risks;43 8.2;4.2 The Potential Signifificance of Altered Normal-Tissue Dose Distributions: Intensity-Modulated Radiation Therapy and Second-Cancer Risks;44 8.3;4.3 Mechanisms of Radiation-Induced Cancer at Radiotherapeutic Doses;44 8.3.1;4.3.1 The Standard Model;44 8.3.2;4.3.2 A More Realistic Model;45 8.4;4.4 An Application: Prospective Estimation of Radiotherapy-Induced Second-Cancer Risks;46 8.5;4.5 Future Directions;46 8.5.1;Acknowledgments;48 8.6;References;48 9;5 Bioengineering in the Repair of Irradiated Normal Tissue by Bone Marrow Derived Stem Cell Populations;51 9.1;5.1 Introduction;51 9.1.1;5.1.1 The New Paradigm for Understanding IonizingIrradiation Tissue Damage;51 9.1.2;5.1.2 General Concepts of Bioengineering for Tissue Repair;52 9.2;5.2 Bone Marrow Origin of Stem Cells for Epithelial Tissues;53 9.2.1;5.2.1 Repopulation of Recipient Target Organs with Bone Marrow Derived Stem Cell Progenitors: A Double Edged Sword;55 9.2.2;5.2.2 Bone Marrow Derived Stem Cells in Bioengineering Repair of Irradiated Oral Cavity and Oropharyngeal Mucosa;55 9.2.3;5.2.3 Bioengineering for Repair of Irradiation Damage in the Esophagus Using Bone Marrow Derived Stem Cell Progenitors;56 9.2.4;5.2.4 Bioengineering of Irradiation Damaged Lung Through Use of Bone Marrow Derived Stem Cell Progenitors;58 9.3;5.3 Summary;60 9.4;References;60 10;6 Development of a Queriable Database for Oncology Outcome Analysis;65 10.1;6.1 Introduction;65 10.2;6.2 Efforts to Date;66 10.2.1;6.2.1 Quality Assurance Review Center;66 10.2.2;6.2.2 Database Function;67 10.2.3;6.2.3 Advanced Technology Consortium;70 10.2.4;6.2.4 American College of Radiology Imaging Network (ACRIN);70 10.2.5;6.2.5 Virtual Imaging Evaluation Workspace (VIEW);71 10.2.6;6.2.6 CaBIG;71 10.3;6.3 Future Strategies for Cancer Clinical Trials;73 10.4;References;75 11;7 Post-Radiation Dysphagia;77 11.1;7.1 Evaluation of the Swallowing Mechanism;78 11.1.1;7.1.1 Objective Evaluation: Instrumental Assessment;78 11.1.2;7.1.2 Objective Evaluation: Observer-Assessed;78 11.1.3;7.1.3 Subjective Evaluation: Patient-Reported Quality of Life;78 11.2;7.2 Baseline Swallowing Function in Patients with Head and Neck Cancer;78 11.3;7.3 Swallowing Disorders Induced by Radiation Alone;79 11.4;7.4 Surgery and